Live Breaking News & Updates on Monitoring Disruption Factors

Harnessing The Power Of AI In MS Diagnosis, Monitoring, And Treatment
By Andrew Thomson, Logan Wright, and Lev Gerlovin, Life Sciences Practice, CRA
Applications of artificial intelligence (AI) are rapidly expanding in healthcare, including the handling of administrative logistics at hospitals, assessment of patient health data, and analysis of novel molecules in drug discovery. A prime example of the future potential of AI is in revolutionizing the way we diagnose, monitor, and treat multiple sclerosis (MS), thereby advancing our understanding of the disease course. Today, MS continues to be a difficult disease to diagnose and treat because the underlying etiology remains unknown. Persistent challenges in the current treatment approach to MS include a lack of reliable biomarkers, making patient diagnosis, disease monitoring, and drug discovery challenging. To maximize the utility of AI in MS, drug developers and medtech manufacturers must strategically incorporate AI solu ....

Andrew Thomson , Lev Gerlovin , Axosim Nervesim , Logan Wright , Google Deepmind , Matia Sadat Borhani , Seyed Sajjad , Life Sciences Practice , Nature Publishing Group , Ai Technology Potential To Identify , Life Sciences , University Of California San Francisco , Disruption Factors , Learning Diagnostic Tools , Monitoring Disruption Factors , Track Patient Disease Progression , California San Francisco , Discovery Disruption Factors , Vitro Model , Identify Novel Biologic Drug Candidates , Critical Assessment , Structure Prediction , Rare Diseases , Matia Sadat , Vectors Machine Based Model , Multiple Sclerosis Using ,